..."pubmed_26928227" /> These discoveries have opened pathways for developing targeted therapies that address specific genetic abnormalities in mesothelioma cells
...gy. His team is currently investigating combinations of immunotherapy with targeted agents, seeking to build on the success of the CheckMate 743 trial while ad
...
24 KB (3,099 words) - 04:00, 9 March 2026
| style="padding:10px;" | CAR-T, Gene Therapy
.../> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref name
...
38 KB (4,755 words) - 03:42, 9 March 2026
...ls|clinical trials]] testing novel combinations of immunotherapy, targeted therapy, and surgical approaches that may not be available at other institutions.<r
...tidisciplinary approach''' — Combines surgery with immunotherapy, targeted therapy, and clinical trials at UCLA
...
22 KB (2,911 words) - 04:00, 9 March 2026
...ion=MSK treats 400+ mesothelioma cases annually with pioneering CAR T-cell therapy and clinical trials. Learn about treatment options and legal compensation.
...words=Memorial Sloan Kettering mesothelioma, MSK cancer center, CAR T-cell therapy mesothelioma, New York mesothelioma treatment, Prasad Adusumilli, Valerie R
...
29 KB (3,631 words) - 20:56, 20 February 2026
...nter's mesothelioma program offers cutting-edge treatment including proton therapy. Learn about care options and legal compensation.
...sothelioma, Houston mesothelioma treatment, Anne Tsao mesothelioma, proton therapy mesothelioma, Texas cancer center, NCI comprehensive cancer center
...
30 KB (3,613 words) - 20:56, 20 February 2026
...> Mayo's current research focuses on combining stereotactic body radiation therapy (SBRT) with immunotherapy, representing the cutting edge of mesothelioma tr
* '''Medical Oncologists''' — designing chemotherapy and targeted therapy protocols
...
29 KB (3,526 words) - 20:56, 20 February 2026
|title=CAR-T Cell Therapy for Mesothelioma: Clinical Trials, Targets & Outcomes
...e to CAR-T cell therapy for malignant mesothelioma. Learn about mesothelin-targeted CAR-T cells, MSKCC clinical trial results showing 72% response rates, intra
...
66 KB (8,673 words) - 02:53, 4 March 2026
...67 discovery through 2020 immunotherapy approval to current CAR-T and gene therapy research.
* '''Survival Progress:''' From ~9 months untreated to 18+ months with modern therapy
...
20 KB (2,490 words) - 20:57, 20 February 2026
...olumab-ipilimumab, pembrolizumab), radiation therapy, TTFields, CAR-T cell therapy, multimodal approaches, and palliative care.
...thelioma, pleurectomy decortication, extrapleural pneumonectomy, radiation therapy mesothelioma, TTFields mesothelioma, CAR-T mesothelioma, palliative care me
...
55 KB (6,918 words) - 12:35, 6 April 2026
* '''Special Expertise:''' Sarcomatoid mesothelioma, cryoablation therapy
* '''Research Focus:''' CAR T-cell therapy, immunotherapy combinations, biomarker development
...
26 KB (3,157 words) - 20:56, 20 February 2026
* '''Special Expertise:''' Sarcomatoid mesothelioma, cryoablation therapy
* '''Research Focus:''' CAR T-cell therapy, immunotherapy combinations, biomarker development
...
26 KB (3,216 words) - 14:57, 9 March 2026
|title=Gene Therapy for Mesothelioma: Clinical Trials, Vectors & Outcomes
...for mesothelioma including suicide gene therapy (HSV-tk), interferon gene therapy (TR002 Phase 3), oncolytic virotherapy (ONCOS-102), tumor suppressor replac
...
67 KB (8,763 words) - 09:18, 6 April 2026
|keywords=mesothelioma clinical trials, CAR-T cell therapy mesothelioma, TEAD inhibitor mesothelioma, VT3989, ISM6331, mesothelioma im
...''' in the first half of 2026, representing a major milestone for targeted therapy in this disease.
...
39 KB (4,791 words) - 23:07, 10 March 2026
...tes]] have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://
* '''New targeted therapies show 86% disease control''' — VT3989, the first TEAD inhibitor, e
...
37 KB (4,489 words) - 20:45, 17 March 2026
...nger predictor (HR 6.12, P=0.0007). Patients receiving mesothelin-targeted therapy who achieved a ≥50% reduction in MPF had dramatically improved progression-
...rvival (22.3 vs. 8.8 months, P=0.004), making MPF a potential predictor of therapy response.<ref name="asco_mpf" /><ref name="oup_mpf" />
...
38 KB (4,844 words) - 09:56, 6 April 2026
...c oncology team pioneered the application of Intensity Modulated Radiation Therapy (IMRT) for mesothelioma, enabling high-dose radiation delivery while minimi
* '''Innovation Focus:''' Pioneer in IMRT (Intensity Modulated Radiation Therapy) for mesothelioma
...
29 KB (3,437 words) - 20:56, 20 February 2026
...e including CheckMate 743 immunotherapy data, MARS 2 trial findings, CAR-T therapy, and current survival statistics.''<ref name="mlcpleural">[https://www.meso
* '''Radiation:''' Often combined with surgery (multimodal therapy)
...
25 KB (3,138 words) - 20:56, 20 February 2026
...="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Gene Therapy Research
...lational researchers developing next-generation treatments like CAR T-cell therapy, and scientists investigating the molecular basis of the disease.<ref name=
...
63 KB (8,220 words) - 22:37, 8 March 2026
...le:italic; border-bottom:1px solid #dee2e6;" | Immune Checkpoint Inhibitor Therapy
...t-line treatment for adults with unresectable MPM — the first new systemic therapy approved for mesothelioma in approximately 16 years, since pemetrexed plus
...
36 KB (4,570 words) - 09:56, 6 April 2026
...ng emerging modalities including gene therapy, cellular therapy, and novel targeted agents.
* '''CAR-T Cell Therapy:''' Previously used for blood cancers; now studied for solid tumors includi
...
43 KB (5,354 words) - 03:51, 9 March 2026
